Actively Recruiting
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
Led by Chengdu New Radiomedicine Technology Co. LTD. · Updated on 2025-05-20
108
Participants Needed
11
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.
CONDITIONS
Official Title
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with hepatocellular carcinoma (CNLC a-a) by clinical, imaging, or pathology based on Chinese guidelines (2024)
- Not suitable for or refusing surgical resection, ablation, or liver transplantation, or at high risk for surgery
- Child-Pugh score of 7 or less
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Adequate organ function
You will not qualify if you...
- Imaging shows or suspects cancer spread outside the liver, including regional lymph nodes
- Previous antitumor treatment for primary hepatocellular carcinoma
- Prior external radiation therapy or intra-arterial brachytherapy
- Liver vascular evaluation results do not meet study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Fujian Cancer Hospital
Fuzhou, Fujian, China
Actively Recruiting
2
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
Actively Recruiting
3
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Actively Recruiting
4
Henan Cancer Hospital
Zhengzhou, Henan, China
Actively Recruiting
5
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Actively Recruiting
6
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Actively Recruiting
7
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Actively Recruiting
8
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China, 210009
Actively Recruiting
9
The First Hospital of China Medical University
Shenyang, Liaoning, China
Actively Recruiting
10
West China Hospital
Chengdu, Sichuan, China
Actively Recruiting
11
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, China
Actively Recruiting
Research Team
G
Gaojun Teng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here